Described herein are compositions comprising a prostaglandin FP receptor agonist (PFPRA) compound and a fatty acid, e.g., oleic acid, that, when topically applied to the skin, locally delivers a therapeutically effective amount of the PFPRA compound or active metabolite thereof to subcutaneous fat under the skin. The therapeutic effect is, for example, reduction of the subcutaneous fat under the skin. Further provided are methods of reducing body fat in a subject comprising topically administering the composition to the subject. The present invention also provides kits comprising the composition and instructions for use.

The disclosure relates to compositions, methods, regimens, and kits for improving the appearance of the skin by applying acetyl trifluoromethylphenyl valylglycine and at least one peeling agent to the skin.

The present disclosure relates to amine hydrofluorides and mixtures of these amine hydrofluorides, and to a process for the preparation of these amine hydrofluorides and their use in oral hygiene compositions.

The present disclosure relates to amine hydrofluorides and mixtures of these amine hydrofluorides, and to a process for the preparation of these amine hydrofluorides and their use in oral hygiene compositions.

Disclosed herein are topical compositions of 5-α reductase inhibitors, such as dutasteride or finasteride, or a pharmaceutically acceptable salt, ester, or derivative thereof and the use of the compositions for the treatment of hair loss secondary to endocrine therapy in patients with breast cancer (Endocrine Therapy-Induced Alopecia or ETIA), androgenetic alopecia (AGA), alopecia areata, and hirsutism. The topical composition is advantageous over the existing oral compositions of 5-α reductase inhibitors because the topical composition is safer and more effective. The topical formulation may allow for a slow release of the active ingredient dutasteride, better penetration at the therapeutically effective amount of dutasteride with an improved safety profile because it does not need to travel through the bloodstream to be efficacious, thereby minimizing the risk of systemic side effects.

Systems and methods for application of cosmetic designs are described. In an embodiment, the system includes a visible light mirror, comprising a first portion being at least partially transparent to visible light; a camera, optically coupled with the visible light mirror to receive visible light via the first portion; an illumination source, physically coupled with the visible light mirror and configured to emit a plurality of discrete wavelength channels; and a computer system, electronically coupled with the camera and the illumination source, and comprising one or more processors and a non-transitory computer readable storage medium storing instructions that, when executed by the one or more processors, cause the one or more processors to perform one or more methods of the present disclosure.

The present disclosure relates to compounds that are capable of inhibiting the mitochondrial pyruvate carrier and promoting hair growth. The disclosure further relates to methods of promoting hair growth or treating conditions or disorders affecting hair growth, such as baldness or alopecia.

The present invention relates to a novel heterocycle derivative, a salt thereof, or an isomer thereof. More specifically, the present invention relates to a novel heterocycle derivative effective for the therapy for hair loss such as androgenic alopecia and alopecia areata and having an excellent preventive effect of hair loss, a salt or isomer thereof, and a composition comprising same as an effective ingredient for prevention of hair loss.

The disclosure belongs to the technical field of medicine, and relates to use of a diketone compound in photodynamic therapy or diagnosis. Particularly, the disclosure relates to use of a compound of formula (I), pharmaceutically acceptable salt or ester, prodrug, stereoisomer, hydrate, solvate or crystal form of the compound, metabolite of each of them, or any combination or mixture thereof in preparation of a drug or a reagent. The drug or the reagent is used for photodynamic therapy or photodynamic diagnosis of a disease or is used for skin beauty by means of photodynamic therapy.

##STR00001##

The present invention relates to the provision of an aqueous emulsion composition for producing a film showing slippery properties containing hydrophobically modified cellulose fibers and at the same time improving water resistance and durability of the film. Since the emulsion composition of the present invention is capable of forming a film having slippery properties, which can be utilized on various surfaces, for example, those in the fields of coatings for ships and bridges, cosmetics, and the like.